PMID- 38327734
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240210
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 17
DP  - 2024
TI  - Association of Systemic Immune-Inflammation Index and Systemic Inflammation 
      Response Index with Diabetic Kidney Disease in Patients with Type 2 Diabetes 
      Mellitus.
PG  - 517-531
LID - 10.2147/DMSO.S447026 [doi]
AB  - PURPOSE: To evaluate the association of the systemic immune-inflammatory index 
      (SII) and systemic inflammatory response index (SIRI) with the clinical and 
      pathological features and progression of diabetic kidney disease (DKD). PATIENTS 
      AND METHODS: We analyzed 303 patients with type 2 diabetes mellitus (T2DM), 
      classifying them into distinct groups: T2DM, early DKD (EDKD), and clinical DKD 
      (Cli-DKD). Variations in SII and SIRI levels across these groups and their 
      association with renal function were assessed. Logistic regression analysis was 
      used to identify independent risk factors for DKD. Additionally, in 43 patients 
      with biopsy-confirmed DKD, we analyzed the relationship between SII, SIRI, and 
      pathological changes. Kaplan-Meier survival analysis and the Cox proportional 
      hazards model were used to assess the influence of SII and SIRI levels on 
      outcomes in patients with DKD. RESULTS: SII and SIRI were significantly higher in 
      the Cli-DKD group than in the T2DM and EDKD groups, and were positively 
      correlated with the urinary albumin-creatinine ratio and negatively correlated 
      with estimated glomerular filtration rate. Notably, SIRI was identified as an 
      independent risk factor for DKD development. Additionally, a lower SII score was 
      associated with a higher cumulative survival rate. CONCLUSION: This study 
      demonstrates an association between SII, SIRI, and renal function in patients 
      with T2DM. A high SIRI was an independent risk factor for DKD, while an elevated 
      SII was associated with an increased risk of kidney disease progression in 
      biopsy-confirmed DKD cases. Our findings underscore the potential implications of 
      utilizing SII and SIRI as cost-effective and readily available inflammatory 
      indicators for monitoring DKD in primary care settings.
CI  - (c) 2024 Liu et al.
FAU - Liu, Wenli
AU  - Liu W
AD  - Department of Nephrology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, People's Republic of China.
FAU - Zheng, Shuran
AU  - Zheng S
AD  - Department of Nephrology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, People's Republic of China.
FAU - Du, Xiaogang
AU  - Du X
AD  - Department of Nephrology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20240201
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC10849098
OTO - NOTNLM
OT  - biomarkers
OT  - diabetes
OT  - immune response
OT  - inflammatory markers
OT  - prognosis
OT  - renal complications
COIS- The authors report no conflicts of interest in this work.
EDAT- 2024/02/08 06:43
MHDA- 2024/02/08 06:44
PMCR- 2024/02/01
CRDT- 2024/02/08 04:09
PHST- 2023/10/28 00:00 [received]
PHST- 2024/01/12 00:00 [accepted]
PHST- 2024/02/08 06:44 [medline]
PHST- 2024/02/08 06:43 [pubmed]
PHST- 2024/02/08 04:09 [entrez]
PHST- 2024/02/01 00:00 [pmc-release]
AID - 447026 [pii]
AID - 10.2147/DMSO.S447026 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2024 Feb 1;17:517-531. doi: 10.2147/DMSO.S447026. 
      eCollection 2024.